In NSCLC cells with sensitive EGFR mutations, EGFR kinase inhibitors can trigger autophagy by disrupting tyrosine phosphorylation of Beclin-1, leading to enhanced tumor growth and resistance to TKI treatment (273). Here, BECN1 is linked to neoplasm.